Urokinase receptor and integrin interactions
- PMID: 12871068
- DOI: 10.2174/1381612033454658
Urokinase receptor and integrin interactions
Abstract
Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase/plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipid-anchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Similar articles
-
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.Mol Biol Cell. 2001 Oct;12(10):2975-86. doi: 10.1091/mbc.12.10.2975. Mol Biol Cell. 2001. PMID: 11598185 Free PMC article.
-
Protease crosstalk with integrins: the urokinase receptor paradigm.Thromb Haemost. 2001 Jul;86(1):124-9. Thromb Haemost. 2001. PMID: 11486997 Review.
-
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
-
Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.J Biol Chem. 2001 Feb 9;276(6):3983-90. doi: 10.1074/jbc.M008220200. Epub 2000 Oct 26. J Biol Chem. 2001. PMID: 11053440
-
Regulation of integrin function by the urokinase receptor.Science. 1996 Sep 13;273(5281):1551-5. doi: 10.1126/science.273.5281.1551. Science. 1996. PMID: 8703217
Cited by
-
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376. Cancers (Basel). 2021. PMID: 34771541 Free PMC article. Review.
-
uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.Res Pharm Sci. 2015 May-Jun;10(3):200-5. Res Pharm Sci. 2015. PMID: 26600846 Free PMC article.
-
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018. Front Oncol. 2018. PMID: 29484286 Free PMC article. Review.
-
Proteases, extracellular matrix, and cancer: a workshop of the path B study section.Am J Pathol. 2004 Apr;164(4):1131-9. doi: 10.1016/S0002-9440(10)63200-2. Am J Pathol. 2004. PMID: 15039201 Free PMC article. Review.
-
The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.Theranostics. 2013 Jun 25;3(7):496-506. doi: 10.7150/thno.4953. Print 2013. Theranostics. 2013. PMID: 23843897 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
